MEDIMMUNE TO PROMOTE DAVID MOTT TO CHIEF EXECUTIVE OFFICER; WAYNE HOCKMEYER TO
                        CONTINUE AS CHAIRMAN OF THE BOARD

Gaithersburg, MD, June 6, 2000 -- MedImmune, Inc. (Nasdaq: MEDI) announced
today that, effective at year end, David M. Mott will succeed Wayne T.
Hockmeyer, Ph.D. as Chief Executive Officer.  Dr. Hockmeyer, who founded and
has led MedImmune since its beginning in 1988, will remain as Chairman of the
Board.

"David has contributed immensely to the growth and success of MedImmune over the
past eight years and the time has come for him to step into the Chief  Executive
role," said Wayne T. Hockmeyer,  Ph.D., Chairman and Chief Executive Officer. "I
obviously also remain deeply  committed to the future success of the company.  I
will remain as Chairman  of the Board and will also  continue to be  responsible
for a variety of activities including working with David on matters of strategic
importance to the company."

Mr. Mott has served as Vice  Chairman and Chief  Financial  Officer  since 1998.
Prior to that he  served  from  1995 - 1998 as  President  and  Chief  Operating
Officer. He was elected to the Board of Directors in 1995. From 1994 - 1995, Mr.
Mott acted as Executive Vice  President and from 1992 - 1994 as Vice  President.
Dr. Hockmeyer added,  "David and I share a common commitment to integrity,  hard
work and the  desire to  continue  the  successful  growth of  MedImmune  in the
future.  Moreover,  we have great enthusiasm for the biotechnology  industry and
the many life saving and important products being developed."

Mr. Melvin D. Booth, MedImmune's President and Chief Operating Officer, will
continue in his current role.  Dr. Hockmeyer said, "Mel has done a tremendous
job since he joined us in October 1998, and I am pleased that Dave and Mel will
be teaming up even further to assure continued excellence in all areas of the
business."

"I have enjoyed  being part of the  tremendous  success at MedImmune  during the
past  eight  years and am  honored  to have the  opportunity  to lead the future
growth of the company as Chief Executive Officer," said Mr. Mott.

MedImmune,   Inc.  is  a  fully  integrated  biotechnology  company  focused  on
developing  and marketing  products that address  medical needs in areas such as
infectious disease, immune regulation and cancer. Headquartered in Gaithersburg,
Maryland,  MedImmune has  manufacturing  facilities  in Frederick,  Maryland and
Nijmegen,  the  Netherlands,  and an oncology  subsidiary in West  Conshohocken,
Pennsylvania.

This announcement may contain,  in addition to historical  information,  certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions.  Actual
results could differ materially from those currently  anticipated as a result of
a  number  of  factors,  including  risks  and  uncertainties  discussed  in the
company's filings with the U.S.  Securities and Exchange  Commission.  MedImmune
cautions that RSV disease occurs primarily during the winter months; the company
believes its operating results will reflect that seasonality for the foreseeable
future.  The company is also developing  several  products for potential  future
marketing. There can be no assurance that such development efforts will succeed,
that such products will receive required  regulatory  clearance or that, even if
such regulatory clearance were received,  such products would ultimately achieve
commercial success.

                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereonto duly authorized.

                                 MEDIMMUNE, INC.
                                -----------------
                                  (Registrant)

June 6, 2000 By:

                           ---------------------------
                          David M. Mott, Vice Chairman
                           and Chief Financial Officer
[{"type": "8-K", "sequence": "1", "filename": "0001.txt", "description": "DAVE MOTT NAMED CHIEF EXECUTIVE OFFICER", "secsgml_size_bytes": 4136}]
{"company-data": {"conformed-name": "MEDIMMUNE INC /DE", "cik": "0000873591", "assigned-sic": "2836", "irs-number": "521555759", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14657", "film-number": "651094"}, "business-address": {"street1": "35 W WATKINS MILL RD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878", "phone": "3014170770"}, "mail-address": {"street1": "35 W WATKINS MILL ROAD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878"}}
MEDIMMUNE TO PROMOTE DAVID MOTT TO CHIEF EXECUTIVE OFFICER; WAYNE HOCKMEYER TO
                        CONTINUE AS CHAIRMAN OF THE BOARD

Gaithersburg, MD, June 6, 2000 -- MedImmune, Inc. (Nasdaq: MEDI) announced
today that, effective at year end, David M. Mott will succeed Wayne T.
Hockmeyer, Ph.D. as Chief Executive Officer.  Dr. Hockmeyer, who founded and
has led MedImmune since its beginning in 1988, will remain as Chairman of the
Board.

"David has contributed immensely to the growth and success of MedImmune over the
past eight years and the time has come for him to step into the Chief  Executive
role," said Wayne T. Hockmeyer,  Ph.D., Chairman and Chief Executive Officer. "I
obviously also remain deeply  committed to the future success of the company.  I
will remain as Chairman  of the Board and will also  continue to be  responsible
for a variety of activities including working with David on matters of strategic
importance to the company."

Mr. Mott has served as Vice  Chairman and Chief  Financial  Officer  since 1998.
Prior to that he  served  from  1995 - 1998 as  President  and  Chief  Operating
Officer. He was elected to the Board of Directors in 1995. From 1994 - 1995, Mr.
Mott acted as Executive Vice  President and from 1992 - 1994 as Vice  President.
Dr. Hockmeyer added,  "David and I share a common commitment to integrity,  hard
work and the  desire to  continue  the  successful  growth of  MedImmune  in the
future.  Moreover,  we have great enthusiasm for the biotechnology  industry and
the many life saving and important products being developed."

Mr. Melvin D. Booth, MedImmune's President and Chief Operating Officer, will
continue in his current role.  Dr. Hockmeyer said, "Mel has done a tremendous
job since he joined us in October 1998, and I am pleased that Dave and Mel will
be teaming up even further to assure continued excellence in all areas of the
business."

"I have enjoyed  being part of the  tremendous  success at MedImmune  during the
past  eight  years and am  honored  to have the  opportunity  to lead the future
growth of the company as Chief Executive Officer," said Mr. Mott.

MedImmune,   Inc.  is  a  fully  integrated  biotechnology  company  focused  on
developing  and marketing  products that address  medical needs in areas such as
infectious disease, immune regulation and cancer. Headquartered in Gaithersburg,
Maryland,  MedImmune has  manufacturing  facilities  in Frederick,  Maryland and
Nijmegen,  the  Netherlands,  and an oncology  subsidiary in West  Conshohocken,
Pennsylvania.

This announcement may contain,  in addition to historical  information,  certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions.  Actual
results could differ materially from those currently  anticipated as a result of
a  number  of  factors,  including  risks  and  uncertainties  discussed  in the
company's filings with the U.S.  Securities and Exchange  Commission.  MedImmune
cautions that RSV disease occurs primarily during the winter months; the company
believes its operating results will reflect that seasonality for the foreseeable
future.  The company is also developing  several  products for potential  future
marketing. There can be no assurance that such development efforts will succeed,
that such products will receive required  regulatory  clearance or that, even if
such regulatory clearance were received,  such products would ultimately achieve
commercial success.

                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereonto duly authorized.

                                 MEDIMMUNE, INC.
                                -----------------
                                  (Registrant)

June 6, 2000 By:

                           ---------------------------
                          David M. Mott, Vice Chairman
                           and Chief Financial Officer